DOH Clinical Pharmacist oral exam prep

Knowledge: Consensus guidance recommends AUC-guided dosing for serious MRSA infection, targeting an AUC24 of 400 to 600 mg.h/L assuming an MIC of 1 mg/L, rather than trough-only monitoring. From the two levels 9 hours apart, the elimination rate constant is about 0.069 per hour, the half-life about 10 hours, and the estimated AUC24 about 750 mg.h/L, above target. A creatinine rise to 1.6 times baseline meets KDIGO stage 1 acute kidney injury. Exposure above the target range is linked with nephrotoxicity, and combination with piperacillin-tazobactam adds risk. Because clearance is falling, any new regimen is an estimate that needs early re-checking.

Management: I would advise holding the next dose now. The daily dose needed for an AUC of about 500 is roughly two thirds of the current dose, so I would suggest about 1 g every 12 hours, or a longer interval if creatinine keeps rising, once a level confirms the concentration has fallen. I would ask for two new levels within 24 to 48 hours and daily creatinine and urine output. I would query whether piperacillin-tazobactam is still needed, since MRSA is the only pathogen. If kidney injury worsens, I would suggest discussing daptomycin with infectious diseases. I would also confirm the line is removed and repeat blood cultures are planned, since source control drives outcome. I would document the calculation and follow up the same day.

Ethics and communication: I would speak directly to the responsible doctor and record whether my advice is accepted. If a dose was about to be given into worsening kidney injury and I could not reach the team, I would escalate through the on-call consultant rather than stay silent. I would not change the order myself unless a facility protocol authorises pharmacist dosing. A drug-related kidney injury should be reported as an adverse drug reaction.

Reference: Rybak MJ et al, Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline of ASHP, IDSA, PIDS and SIDP (Am J Health Syst Pharm 2020); Bauer LA, Applied Clinical Pharmacokinetics (3rd ed, 2014)

Knowledge: This is supratherapeutic anticoagulation from a well-known interaction: sulfamethoxazole inhibits CYP2C9, the main pathway for the more potent S-warfarin. Her CHA2DS2-VASc score is 5, so stroke risk is high and overcorrection also harms. For an INR above 10 without bleeding, the ACCP guideline suggests stopping warfarin and giving oral vitamin K, while an INR of 4.5 to 10 without bleeding does not routinely need it. Major bleeding would instead need intravenous vitamin K 5 to 10 mg with four-factor prothrombin complex concentrate. I would screen for occult bleeding and check for other new drugs, illness or reduced intake.

Management: I would advise holding warfarin and recommend a low oral dose of vitamin K, commonly 2 to 2.5 mg, given in clinic today. I would ask the prescriber to review the antibiotic against the urine culture and choose an agent without a strong warfarin interaction that suits her renal function. I would repeat the INR in 24 hours, then every 1 to 2 days until in range. I would advise restarting warfarin once the INR is below 3, perhaps at a slightly lower dose until the antibiotic ends, with weekly INRs for two weeks. I would give clear advice on bleeding warning signs. I would not give large doses of vitamin K, which cause resistance for days. I would also discuss whether a direct oral anticoagulant suits her.

Ethics and communication: The interaction was preventable, so I would inform the prescribing clinic in writing and record it as a medication incident and adverse drug reaction in line with facility policy. I would explain what happened to her and, with her permission, her family, without blaming colleagues. I would document the INR, advice and follow-up plan and add an interaction alert to her record.

Reference: Holbrook A et al, Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed, ACCP Evidence-Based Clinical Practice Guidelines (Chest 2012); 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation

Knowledge: This is low-dose methotrexate toxicity from a daily instead of weekly dosing error, one of the best-known high-alert medication errors. Mucositis with neutropenia and thrombocytopenia shows marrow suppression, which can progress to sepsis, bleeding and death. Folinic acid (calcium folinate) bypasses the blocked dihydrofolate reductase and works best when started early. Risk rises with renal impairment, older age and interacting drugs such as trimethoprim or NSAIDs. Using the NCC MERP index, this error reached the patient and caused harm requiring intervention.

Management: I would tell her to stop methotrexate and keep the remaining tablets. I would arrange same-hour assessment by the treating physician or emergency department with a direct handover. I would advise that folinic acid start at once, dosed per protocol with haematology or poison centre advice, with a methotrexate level, renal and liver function, daily blood counts and mouth care. Febrile neutropenia would need empirical antibiotics. I would check her other medicines for interactions. I would then quarantine the stock, check other prescriptions from the same period and complete an incident report the same day. Later, I would support the root cause analysis and suggest system fixes such as weekly-dose software prompts, mandatory counselling and labels stating the day of the week.

Ethics and communication: She is owed an honest explanation that the label was wrong, an apology and a plan, recorded in her notes, consistent with Federal Decree-Law No. 4 of 2016 on Medical Liability. I would inform my manager and speak to the colleague privately, making clear the error cannot be hidden or the label replaced. The incident goes through the facility reporting system and any regulator reporting in line with DOH requirements. A just culture approach looks at the system first while still addressing individual performance if needed.

Reference: ISMP List of High-Alert Medications in Acute Care Settings; WHO Medication Without Harm: Global Patient Safety Challenge on Medication Safety (2017); NCC MERP Index for Categorizing Medication Errors

Knowledge: This is E. coli bacteraemia from pyelonephritis, responding well, with a susceptible organism. Meropenem is a WHO Watch antibiotic, and unnecessary carbapenem use drives carbapenem-resistant Enterobacterales, a serious problem in the Gulf region. Vancomycin has no role with no Gram-positive organism. Oral step-down suits a stable, afebrile patient who can absorb oral drugs once the source is controlled. A randomised trial showed 7 days was non-inferior to 14 days in Gram-negative bacteraemia when patients were stable with source control. Ciprofloxacin or co-trimoxazole, matched to susceptibility, has good oral bioavailability.

Management: I would first confirm obstruction or abscess has been excluded and check renal function, allergies and interactions. I would recommend stopping vancomycin today and switching to oral ciprofloxacin 500 mg twice daily or co-trimoxazole 960 mg twice daily, for 7 days in total from the first effective dose. I would speak to the consultant directly and politely, presenting the cultures, the trial evidence and the hospital guideline, and offer an infectious diseases opinion. If they still decline, I would document my advice and their reason and raise the case through the stewardship programme for audit and feedback. I would not change the prescription myself. I would follow up at discharge planning.

Ethics and communication: The consultant holds clinical responsibility, and my role is clear, evidence-based advice that is recorded. Disagreement should be respectful and never in front of the patient, who deserves a consistent explanation from the team. Overuse of reserve antibiotics harms future patients, so escalation through stewardship structures is legitimate, not a personal challenge.

Reference: Barlam TF et al, Implementing an Antibiotic Stewardship Program: Guidelines by IDSA and SHEA (Clin Infect Dis 2016); WHO AWaRe (Access, Watch, Reserve) Antibiotic Book (2022)

Knowledge: By Cockcroft-Gault with actual weight her creatinine clearance is about 20 mL/min, and eGFR may overestimate function in a small older woman. Gabapentin is renally cleared and her dose is far above the range for this clearance, a likely cause of her drowsiness. Metformin should be stopped when eGFR is below 30 because of lactic acidosis risk. Enoxaparin accumulates below a clearance of 30 mL/min, so the treatment dose should be 1 mg/kg once daily, or unfractionated heparin used. The Beers Criteria advise avoiding nitrofurantoin below a clearance of 30 mL/min. I would also ask why kidney function has worsened.

Management: I would recommend holding gabapentin and, if still needed, restarting at a much lower dose within the renal handbook range once she is alert. I would recommend stopping metformin and checking glucose and HbA1c, with the team choosing a renally suitable alternative. I would advise enoxaparin 50 mg once daily, with the next dose 24 hours after the last, or unfractionated heparin if renal function is unstable. I would ask for the urine culture and suggest an antibiotic suited to her clearance. I would recommend daily creatinine and potassium and check for other nephrotoxic or potassium-raising drugs. All advice would be discussed with the doctor, documented and reviewed at 48 hours.

Ethics and communication: While she lacks capacity, decisions should involve her family or guardian, and she should be informed when she recovers. I would present the problem as a system failure to check renal function at prescribing, not individual blame. Any harm should be reported as a medication incident in line with facility policy, and I would suggest a renal dosing alert in electronic prescribing.

Reference: Ashley C, Dunleavy A, The Renal Drug Handbook (5th ed, 2019); American Geriatrics Society 2023 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults; KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease

Knowledge: High withdrawals, low documented pain, repeated waste with the same witness and patient complaints are recognised indicators of diversion. Diversion harms patients denied analgesia, may signal an impaired colleague, and creates legal risk for the facility. The data show a pattern for investigation, not proof, and other explanations such as documentation habits or patient mix must be considered. Good governance separates the detection, investigation and support roles. Controlled drug handling in the UAE is strictly regulated under federal law and DOH requirements.

Management: I would first check the data objectively: prescriptions, administration times, pain scores and waste records, compared with peers on matched shifts. I would not confront the nurse or discuss it on the ward. I would report the findings in confidence to the pharmacy and nursing directors under the facility diversion policy so that a formal investigation starts. I would advise safeguards that single no one out, such as unannounced counts and rotating or pharmacist witnesses for waste. If she appears impaired at work, the manager must remove her from duty at once. Later I would support system controls, such as monthly anomalous usage reports. I would keep a dated factual record of what I found and whom I told.

Ethics and communication: My duty to patient safety and the law means I cannot ignore the pattern because the nurse is popular. She is entitled to confidentiality and a fair process until findings are proven. If substance misuse is found, the facility should offer support alongside any reporting required by UAE law and DOH. Patients who may have been denied analgesia deserve review and an honest explanation if confirmed.

Reference: ASHP Guidelines on Preventing Diversion of Controlled Substances (2022)